Abstracts tagged "Cardiovascular disease"

Abstract Number: 2362 • 2017 ACR/ARHP Annual Meeting
Novel Biomarkers for the Prediction of Subclinical Coronary Artery Atherosclerosis in Patients with Rheumatoid Arthritis
Joan Bathon¹, Jenny Van Eyk², Nick Knowlton³, Ivan Ferraz-Amaro⁴, Jon T. Giles⁵, C. Michael Stein⁶, Mary Chester M. Wasko⁷ and Michael Centola⁸, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Advanced Clinical BioSystems Research Institute , Cedars-Sinai Medical Center, Los Angeles, CA, ³Department of Arthritis and Clinical Rheumatology, Oklahoma Medical Research Foundation, Oklahoma, OK, ⁴Rheumatology, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, ⁵Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁶Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁷Lupus Center, Pittsburgh, PA, ⁸Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma, OK
Background/Purpose: Cardiovascular (CV) disease risk prediction models, that were originally developed for use in the general population, have been found to have suboptimal performance in…
Abstract Number: 2937 • 2017 ACR/ARHP Annual Meeting
Genetic Variants in HLA-C and Class I Pathway Genes Influence Susceptibility to Kawasaki Disease
Chisato Shimizu¹, Jihoon Kim², Hariklia Eleftherohorinou³, Victoria Wright³, Long Hoang⁴, Adriana Tremoulet⁵, Alessandra Franco⁶, Martin Hibberd⁴, Atsushi Takahashi^7,8, Michiaki Kubo⁹, Kaoru Ito¹⁰, Toshihiro Tanaka^10,11, Yoshihiro Onouchi^10,12, Lachlan Coin³, Michael Levin³, Jane Burns¹³ and Hiroko Shike¹⁴, ¹Pediatrics, University of California San Diego, School of Medicine, La Jolla, CA, ²Medicine, University California San Diego, School of Medicine, Division of Biomedical Informatics, La Jolla, CA, ³Imperial College London, London, United Kingdom, ⁴Genome Institute of Singapore, Singapore, Singapore, ⁵Pediatrics, University California San Diego, School of Medicine, La Jolla, CA, ⁶Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, ⁷Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, ⁸Department of Genomic Medicine, National Cerebral And Cardiovascular Center, Suita, Japan, ⁹RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, ¹⁰Laboratory for Cardiovascular Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, ¹¹Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo, Japan, ¹²Department of Public Health, Chiba University Graduate School of Medicine, Chiba, Japan, ¹³Pediatrics, University California San DIego, School of Medicine, San Diego, CA, ¹⁴Penn State Hershey Medical Center, Hershey, PA
Background/Purpose: Host genetics influence susceptibility to Kawasaki disease (KD), an acute pediatric vasculitis, and genome wide association studies (GWAS) have detected variants with modest effects…
Abstract Number: 146 • 2017 ACR/ARHP Annual Meeting
Major Cardiovascular Events Among an Inception Cohort of Seniors with Rheumatoid Arthritis
Jessica Widdifield^1,2, Michael Paterson², Anjie Huang², Bindee Kuriya³, Carter Thorne⁴, Janet E. Pope⁵ and Sasha Bernatsky⁶, ¹Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³Sinai Health System, University of Toronto, Toronto, ON, Canada, ⁴Southlake Regional Health Centre, Newmarket, ON, Canada, ⁵Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁶Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: We previously observed that incident RA patients have an increased risk of cardiovascular (CV) mortality relative to the general population in Ontario. Our aim…
Abstract Number: 1095 • 2017 ACR/ARHP Annual Meeting
Increasing Lipid Panel Monitoring in a Rheumatology Clinic
Anju Mohan¹ and Beth Scholz², ¹Internal Medicine-Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Internal Medicine - Rheumatology, University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Patients with autoimmune conditions are at increased risk for cardiovascular disease (CVD) compared to the general population. It is not routine practice at UT…
Abstract Number: 1610 • 2017 ACR/ARHP Annual Meeting
The Impact of Alcohol Use on Cardiovascular Events and Overall Mortality in Women with Systemic Lupus Erythematosus
April Jorge¹, Leo Lu², Yuqing Zhang³, Sharan K. Rai⁴ and Hyon K. Choi⁴, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Women with SLE have an increased risk of cardiovascular disease (CVD) and premature death. In the general population, moderate alcohol intake is associated with…
Abstract Number: 2363 • 2017 ACR/ARHP Annual Meeting
Does Galectin-3 Have Utility As a Biomarker of Subclinical Cardiovascular Disease in RA Patients Independently of RA Disease Activity?
Amanda Nussdorf¹, Isabelle Amigues² and Joan Bathon³, ¹Columbia University Medical Center, New York, NY, ²Division of Rheumatology, Columbia University Medical Center, New York, NY, ³Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY
Background/Purpose: Galectin-3 is a beta-galactoside-binding lectin and is a marker of cardiovascular disease (CVD) in the general population. However, galectin-3 level is also elevated in…
Abstract Number: 2960 • 2017 ACR/ARHP Annual Meeting
Cardiovascular and Cerebrovascular Comorbidities of Juvenile Dermatomyositis in United States Children
Jonathan I. Silverberg¹, Lauren Kwa², Michael C. Kwa², Anne Laumann² and Kaveh Ardalan^3,4, ¹Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Departments of Pediatrics and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
Background/Purpose: Juvenile dermatomyositis (JDM) is an autoimmune disease that causes vasculopathy and inflammation of skin and muscles. Previous studies in adult dermatomyositis suggest increased risks…
Abstract Number: 147 • 2017 ACR/ARHP Annual Meeting
Performance of Cardiovascular Risk Age and Vascular Age Estimations in Predicting Cardiovascular Events in Rheumatoid Arthritis
Grunde Wibetoe¹, Cynthia S. Crowson², Joseph Sexton³, Silvia Rollefstad¹, Eirik Ikdahl¹, George D. Kitas⁴, Piet van Riel⁵, Sherine E. Gabriel⁶, Tore K. Kvien⁷, Karen Douglas⁸, Aamer Sandoo^8,9, Elke Arts⁵, Solveig Wållberg-Jonsson¹⁰, Solbritt Rantapää Dahlqvist¹⁰, George Karpouzas¹¹, Patrick H. Dessein^12,13, Linda Tsang¹⁴, Hani El-Gabalawy¹⁵, Carol A Hitchon¹⁵, Virginia Pascual-Ramos¹⁶, Irazu Contreras-Yañez¹⁷, Petros P Sfikakis¹⁸, Evangelia Zampeli¹⁹, Miguel Angel González-Gay²⁰, Alfonso Corrales²¹, Iris J. Colunga-Pedraza²², Dionicio A. Galarza-Delgado²³, Jose Ramon Azpiri-Lopez²⁴ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Medicine, Division of Rheumatology,Mayo Clinic, Rochester, MN, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴School of Sport, Exercise and Rehabilitation, University of Birmingham, Birmingham, United Kingdom, ⁵Department of Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁶Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁷NORDMARD, Oslo, Norway, Oslo, Norway, ⁸Dudley Group NHS Foundation Trust, West Midlands, United Kingdom, ⁹School of Sport, Health and Exercise Sciences, Bangor University, Bangor, United Kingdom, ¹⁰University of Umeå, Umeå, Sweden, ¹¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ¹²Vrije Universiteit Brussel, Brussel, Belgium, ¹³Universitair Ziekenhuis Brussel, Brussel, Belgium, ¹⁴Rheumatology, Universitair Ziekenhuis Brussel, Brussels, Belgium, ¹⁵University of Manitoba, Winnipeg, MB, Canada, ¹⁶Instituto Nacional de Ciencias Médicas y Nutrició, Mexico City, Mexico, ¹⁷Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ¹⁸First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ¹⁹Institute of Autoimmune Systemic and Neurological Diseases, National and Kapodistrian University of Athens, Athens, Greece, ²⁰Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Johannesburg, South Africa, ²¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²²Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ²³Chief of Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ²⁴Cardiology, Hospital Universitario, UANL., Monterrey, Mexico
Background/Purpose: Rheumatoid arthritis (RA) patients are at high risk of cardiovascular disease (CVD). Risk algorithms for the general population lack precision when applied to RA…
Abstract Number: 1113 • 2017 ACR/ARHP Annual Meeting
Risk of Cardiovascular Events in Older Patients with Gout Initiating Probenecid Versus Allopurinol: A Population-Based Cohort Study
Seoyoung C. Kim¹, Tuhina Neogi², Eun Ha Kang³, Jun Liu⁴, Rishi J. Desai⁵, MaryAnn Zhang⁶ and Daniel H. Solomon⁷, ¹Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Gout is associated with an increased risk of cardiovascular (CV) disease including myocardial infarction (MI), stroke and heart failure (HF). Although both probenecid and…
Abstract Number: 1620 • 2017 ACR/ARHP Annual Meeting
Habitual Physical Activity, Sedentary Behavior and Cardiovascular Disease Risk Burden in Systemic Lupus Erythematosus (SLE)
Alexandra Legge¹, Chris Blanchard¹ and John G. Hanly², ¹Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ²Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Patients with SLE are at increased risk for atherosclerotic cardiovascular disease (ASCVD). As sedentary behavior and lack of physical activity (PA) have been identified…
Abstract Number: 2365 • 2017 ACR/ARHP Annual Meeting
Poor Cardiovascular Risk Management in Rheumatoid Arthritis Patients Despite an Explicit Cardiovascular Risk Management Program
Maaike Heslinga¹, Inge van den Oever², E. Griep³, Hanneke Griep-Wentink³, Yvo M. Smulders⁴, WF Lems⁵, Maarten Boers⁶, Alexandre Voskuyl⁷, Mike J.L. Peters⁴, Dirkjan van Schaardenburg² and Michael Nurmohamed⁸, ¹Amsterdam Rheumatology immunology Center | Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ³Rheumatology, Antonius Hospital, Sneek, Netherlands, ⁴Internal Medicine, VU University Medical Center, Amsterdam, Netherlands, ⁵Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁶Epidemiology & Biostatistics, VU Univ Medical Center F-wing, Amsterdam, Netherlands, ⁷Department of Rheumatology, Amsterdam Rheumatology and immunology Center - location VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁸Rheumatology, Reade, Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands
Background/Purpose: In 2011, we started a cardiovascular (CV) risk management program for rheumatoid arthritis (RA) patients visiting Reade in the Netherlands. We previously reported the…
Abstract Number: 2965 • 2017 ACR/ARHP Annual Meeting
Non-Invasive Imaging Methods for Evaluating the Cardiovascular Involvement in Patients with Rheumatoid Arthritis before and after 18 Months of Treatment with Anti-TNF Drugs
Fabiola Atzeni¹, Luigi Gianturco², Laura Boccassini³, Piercarlo Sarzi-Puttini³ and Maurizio Turiel⁴, ¹Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ²Beato Matteo” Hospital, GSD Foundation, Vigevano, Italy, Vigevano, Italy, ³Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, ⁴IRCCS, Galeazzi Orthopedic Institute, Dept. Biomedical Sciences for Health, University of Milan, Milan, Italy
Background/Purpose: The aim of this study was to evaluate left ventricular myocardial function with two- dimensional speckle tracking echocardiography (STE), in addition to conventional Doppler…
Abstract Number: 284 • 2017 ACR/ARHP Annual Meeting
Metabolic Activity Sustains Macrophage Cytokine Production in Rheumatoid Arthritis and Coronary Artery Disease
Cornelia M. Weyand¹, Markus Zeisbrich¹, Lukas Brosig², Barbara Wallis¹, Niall Roche³, Janice Lin¹ and Jorg Goronzy⁴, ¹Medicine: Immunology and Rheumatology, Stanford University, Stanford, CA, ²Medicine: Immunology and Rheumatology, Stanford University, Stanfod, CA, ³The Arthritis Center, Pleasanton, CA, ⁴Medicine/Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Accelerated atherosclerosis has become increasingly recognized as a complication of chronic inflammatory disease, such as in patients with rheumatoid arthritis (RA). RA patients have…
Abstract Number: 1130 • 2017 ACR/ARHP Annual Meeting
Can Alcohol Intake in Moderation Lower the Risk of Myocardial Infarction and Mortality Even Among Gout Patients?
Sarah Keller¹, Sharan K. Rai², Na Lu¹, April Jorge³, Yuqing Zhang⁴ and Hyon K. Choi², ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Alcohol is a well-established risk factor for gout. However, more than 60 prospective studies have also shown that moderate alcohol intake is associated with…
Abstract Number: 1642 • 2017 ACR/ARHP Annual Meeting
Role of Plaque in Predicting Cardiovascular Events in Women with Lupus over a 20 Year Followup
Erika Joyce¹, Linda Santelices², Jennifer Mall², Kristy Huysman², Amy Xiaoqin Tang³, Michael Anderson², Jennifer Elliott⁴, Amy H. Kao^5,6 and Susan Manzi², ¹Internal Medicine, Allegheny Health Network, Pittsburgh, PA, ²Medicine, Allegheny Health Network, Pittsburgh, PA, ³Lupus Center of Excellence, Allegheny Health Network Research Institute, Pittsburgh, PA, ⁴Allegheny Health Network, Pittsburgh, PA, ⁵EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁶EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA), Billerica, MA
Background/Purpose: The increased risk of premature cardiovascular disease (CVD) in systemic lupus erythematosus (SLE) patients has been well reported. Multiple series have demonstrated a higher…

« Previous Page
1
…
8
9
10
11
12
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].